|
Association of MDM2 SNP309 with lung cancer |
||||
| gender |
Genotype |
OR |
95% CI |
p-value |
|
|
||||
| men* |
TG vs. GG |
1.1 |
0.7 – 2.0 |
0.630 |
| men* |
TT vs. GG |
1.2 |
0.7 – 2.2 |
0.504 |
| women* |
TG vs. GG |
0.9 |
0.5 – 1.6 |
0.723 |
| women* |
TT vs. GG |
0.8 |
0.5 – 1.3 |
0.565 |
|
|
||||
| histology |
||||
|
|
||||
| NSCLC-Adenocarcinoma** |
TG vs. GG |
1.0 |
0.6 – 1.7 |
0.991 |
| NSCLC-Adenocarcinoma** |
TT vs. GG |
1.0 |
0.6 – 1.8 |
0.890 |
| other NSCLC** |
TG vs. GG |
1.0 |
0.6 – 1.8 |
0.873 |
| other NSCLC** |
TT vs. GG |
0.9 |
0.5 – 1.6 |
0.751 |
| SCLC** |
TG vs. GG |
1.0 |
0.5 – 1.9 |
0.980 |
| SCLC** |
TT vs. GG |
1.2 |
0.6 – 2.1 |
0.637 |
|
|
||||
| smoking exposure (packyears) |
||||
|
|
||||
| lightly exposed (11–20 PY)*** |
TT vs. GG |
1.0 |
0.6 – 1.8 |
0.928 |
| lightly exposed (11–20 PY)*** |
TG vs. GG |
1.0 |
0.5 – 1.7 |
0.857 |
| moderately exposed (21–30 PY)*** |
TT vs. GG |
1.0 |
0.6 – 1.7 |
0.960 |
| moderately exposed (21–30 PY)*** |
TG vs. GG |
0.9 |
0.6 – 1.6 |
0.822 |
| highly exposed (31++ PY)*** |
TT vs. GG |
0.9 |
0.5 – 1.4 |
0.595 |
| highly exposed (31++ PY)*** |
TG vs. GG |
0.8 |
0.5 – 1.3 |
0.369 |
|
*conditional to age-strata (3 groups: ≤ 40 years, 41–45 years, 46–50 years), adjusted for smoking exposure; **conditional to age/gender-strata (6 groups) and adjusted for smoking exposure; ***conditional to age/gender-strata (6 groups) | ||||
Mittelstrass et al. BMC Cancer 2008 8:113 doi:10.1186/1471-2407-8-113 |
||||